Recently, IPHASE, in conjunction with the Perelman School of Medicine at the University of Pennsylvania, co-authored an article in the journal Antibody Therapeutics (IF=4.56) titled "Development of a novel humanised anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential", the study developed a novel humanised anti-TSLP monoclonal antibody HZ-1127 and tested its binding affinity, specificity and ability to inhibit TSLP.
Thymic stromal lymphopoietin (TSLP) is a member of the IL-2 cytokine family, and dysregulation of the TSLP-TSLP receptor (TSLPR) pathway has been associated with the development of allergic diseases as well as a wide range of cancers, including solid and haematological tumours. Therefore, specific binding of TSLP using antibodies is a potential strategy for the treatment of allergic diseases and cancers. The FDA currently approves Tezepelumab, a human anti-TSLP monoclonal antibody, for the treatment of severe asthma.
IPHASE has developed for the first time in this study a new human anti-TSLP monoclonal antibody, HZ-1127, with exceptional affinity and specificity to selectively bind TSLP cytokines. Compared with Tezepelumab, the epitopes bound to TSLP by both are highly similar, and HZ-1127 has a stronger potency to block the interaction between TSLP and TSLPR. HZ-1127 also showed superior effects to Tezepelumab in inhibiting TSLP-induced STAT5 activation and CCL17 and CCL22 chemokine secretion.HZ-1127 may be a potential therapeutic agent for allergic diseases and cancer.
The antibody development technology involved in this study and the relevant recombinant proteins and antibodies used in the experiments were provided by IPHASE.
Fig.1 Identification of monoclonal antibody HZ-1127
Fig.2 Inhibition of TSLP-induced CCL17 and CCL22 chemokine secretion analysed in PBMCs
Fig.3 Schematic representation of the inhibitory effect of HZ-1127 and Tezepelumab on TSLP signalling
Thymic stromal lymphopoietin (TSLP) is a member of the IL-2 cytokine family, and dysregulation of the TSLP-TSLP receptor (TSLPR) pathway has been associated with the development of allergic diseases as well as a wide range of cancers, including solid and haematological tumours. Therefore, specific binding of TSLP using antibodies is a potential strategy for the treatment of allergic diseases and cancers. The FDA currently approves Tezepelumab, a human anti-TSLP monoclonal antibody, for the treatment of severe asthma.
IPHASE has developed for the first time in this study a new human anti-TSLP monoclonal antibody, HZ-1127, with exceptional affinity and specificity to selectively bind TSLP cytokines. Compared with Tezepelumab, the epitopes bound to TSLP by both are highly similar, and HZ-1127 has a stronger potency to block the interaction between TSLP and TSLPR. HZ-1127 also showed superior effects to Tezepelumab in inhibiting TSLP-induced STAT5 activation and CCL17 and CCL22 chemokine secretion.HZ-1127 may be a potential therapeutic agent for allergic diseases and cancer.
The antibody development technology involved in this study and the relevant recombinant proteins and antibodies used in the experiments were provided by IPHASE.
Fig.1 Identification of monoclonal antibody HZ-1127
Fig.2 Inhibition of TSLP-induced CCL17 and CCL22 chemokine secretion analysed in PBMCs
Fig.3 Schematic representation of the inhibitory effect of HZ-1127 and Tezepelumab on TSLP signalling
Post time: 2024-07-27 16:34:37